Pulmonary arterial volume and mortality in smokers without chronic obstructive pulmonary disease.

Authors

Shanshan Wang, Mehran Azimbagirad, Daryl O Cheng, Tanya Patrick, Amyn Bhamani, Robert Chapman, Daisuke Yamada, Arjun Nair, Gabrielle Baxter, Ashkan Pakzad, Adam Szmul, Bojidar Rangelov, Jason Lim, Vichayasit Tantayapong, David A Lynch, Gregory L Kinney, Joanna Pepke-Zaba, Hakim Ghani, Caitlin Fermoyle, Daniel C Alexander, SUMMIT Consortium, Sam M Janes, John R Hurst, Joseph Jacob

Published in

Respiratory medicine. Pages 109134. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

Pulmonary vascular remodelling is a recognised consequence of chronic tobacco exposure and may have prognostic associations even without airway obstruction. The association between the extraparenchymal pulmonary artery (ePA) and all-cause mortality in current and ex-smokers without COPD has not been demonstrated and replicated in large cohort studies.
Retrospective analysis of prospective data from the COPDGene cohort, with validation in the SUMMIT lung cancer screening trial. ePA volume and lung volume were measured on chest CT using automated deep learning-based segmentation. All-cause mortality risk was estimated using Cox proportional hazards models, adjusted for age, gender, body mass index, smoking status, pack-years, emphysema extent, Charlson Comorbidity Index, ILA presence, and FEV₁.
4,719 participants without COPD were included in the discovery COPDGene cohort (median age 56 [51-63] years, 50% male) and 3,391 in the SUMMIT validation cohort (median age 64 [59-69] years, 61% male). There were 600 deaths (13%; 39,531 person-years) in COPDGene and 214 deaths (6.3%; 16,629 person-years) in SUMMIT. Each one-standard-deviation (∼25mL) increase in ePA volume was independently associated with all-cause mortality in COPDGene (aHR 1.42 [1.25-1.60], p<0.001) and SUMMIT (aHR 1.23 [1.07-1.42], p=0.003). A parsimonious, ridge-regularised multivariable model developed in COPDGene showed good discrimination (C-index 0.70 [0.65-0.74]) and calibration (integrated calibration index 2.1% [1.3-6.4]) when validated in SUMMIT.
Increasing ePA volume in current and ex-smokers without COPD is associated with all-cause mortality and could represent a candidate imaging marker for cohort enrichment in studies of pulmonary vasculopathy, although this requires prospective validation.
N/A.

PMID:
42838239
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.